| 2022 | 2021 | 2020 | ||||
|---|---|---|---|---|---|---|
| Gross margin | -37,2 k € | -272.8% | -10,0 k € | -454.5% | -1,8 k € | |
| EBITDA | -127,4 k € | -92.6% | -66,2 k € | -2552.7% | -2,5 k € | |
| Operating profit | -127,4 k € | -92.6% | -66,2 k € | -2552.7% | -2,5 k € | |
| Profit/loss | -128,3 k € | -91.9% | -66,9 k € | -2569.8% | -2,5 k € | |
| Equity | -179,1 k € | -252.8% | -50,8 k € | -415.4% | 16,1 k € | |
| Total assets | 327,8 k € | -28.2% | 456,9 k € | +111.4% | 216,1 k € | |
| Cash | 206,6 k € | -54.7% | 455,8 k € | +111.1% | 215,9 k € | |
| Debts | 506,9 k € | -0.1% | 507,6 k € | +153.8% | 200,0 k € | |
Private limited company · Marche-en-Famenne · incorporated on 30/07/2019
Private limited company loss-making in the latest fiscal year. Cash position declining (-54.7%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
THERACELL ADVANCED BIOTECHNOLOGY (Belgium) is a Private limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Marche-en-Famenne.